Literature DB >> 9185142

Distribution of capsular types and antimicrobial susceptibility of invasive isolates of Streptococcus pneumoniae in Colombian children. Pneumococcal Study Group in Colombia.

E Castañeda1, A L Leal, O Castillo, F De La Hoz, M C Vela, M Arango, H Trujillo, A Levy, M E Gama, M Calle, M L Valencia, W Parra, N Agudelo, G I Mejía, S Jaramillo, F Montoya, H Porras, A Sánchez, D Saa, J L Di Fabio, A Homma.   

Abstract

Streptococcus pneumoniae is the leading bacterial cause of childhood pneumonia in the developing world. This study describes the type distribution and antimicrobial susceptibility of invasive pneumococcal isolates from Colombian children and is part of the Sistema Regional de Vacunas (SIREVA), a PAHO regional initiative designed to determine the ideal serotype composition of a protein polysaccharide pneumococcal conjugate vaccine for use in children less than 5 years old in Latin America. In Colombia, during the study period, centres in Bogota, Medellin, and Cali collected 324 S. pneumoniae isolates from invasive diseases, 238 (73.5%) from children under the age of 2. Pneumonia was the clinical diagnosis in 41.3% cases, meningitis in 41%, and sepsis in 11.2%. The seven most frequent types included 14(21.9%), 5(10.5%), 23F(9.6%), 1(9%), 6B(9%), 19F(7.1%), and 6A(6.2%). The frequency of diminished susceptibility to penicillin (DSP) was 12%, with 8.9% of isolates showing intermediate level resistance and 3.1% showing high level resistance. Among DSP isolates, 23% were also resistant to cefotaxime, 33.3% to erythromycin, 48.7% to chloramphenicol, and 74.3% to trimethoprim/sulfamethoxazole. Multiple resistance was detected in 59% of the isolates that have DSP. Penicillin resistance was associated with types 23F (53.8%) and 14 (25.6%). These data provides information on capsular types prevalent in Colombia that will not only allow the formulation of an ideal vaccine for the region but also reinforce the need for ongoing regional surveillance.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9185142     DOI: 10.1089/mdr.1997.3.147

Source DB:  PubMed          Journal:  Microb Drug Resist        ISSN: 1076-6294            Impact factor:   3.431


  11 in total

1.  Antimicrobial susceptibilities and serotype distribution of Streptococcus pneumoniae isolates from a Low socioeconomic area in Lima, Peru.

Authors:  Anna R Cullotta; H D Kalter; Jose Delgado; Robert H Gilman; Richard R Facklam; Billie Velapatino; Jorge Coronel; Lilia Cabrera; M Urbina
Journal:  Clin Diagn Lab Immunol       Date:  2002-11

2.  Dissemination of Streptococcus pneumoniae clone Colombia(5)-19 in Latin America.

Authors:  Liliana Gamboa; Teresa Camou; María Hortal; Elizabeth Castañeda
Journal:  J Clin Microbiol       Date:  2002-11       Impact factor: 5.948

Review 3.  Humoral immune responses to Streptococcus pneumoniae in the setting of HIV-1 infection.

Authors:  Lumin Zhang; Zihai Li; Zhuang Wan; Andrew Kilby; J Michael Kilby; Wei Jiang
Journal:  Vaccine       Date:  2015-06-30       Impact factor: 3.641

4.  Dissemination of a chloramphenicol- and tetracycline-resistant but penicillin-susceptible invasive clone of serotype 5 Streptococcus pneumoniae in Colombia.

Authors:  M Tamayo; R Sá-Leão; I Santos Sanches; E Castañeda; H de Lencastre
Journal:  J Clin Microbiol       Date:  1999-07       Impact factor: 5.948

5.  Population-based survey of antimicrobial susceptibility and serotype distribution of Streptococcus pneumoniae from meningitis patients in Salvador, Brazil.

Authors:  Joice Neves Reis; Soraia Machado Cordeiro; Steven J Coppola; Kátia Salgado; Maria G S Carvalho; Lúcia M Teixeira; Terry A Thompson; Richard R Facklam; Mitermayer G Reis; Albert I Ko
Journal:  J Clin Microbiol       Date:  2002-01       Impact factor: 5.948

6.  Vaccine-induced human antibodies to PspA augment complement C3 deposition on Streptococcus pneumoniae.

Authors:  Martina M Ochs; William Bartlett; David E Briles; Bryony Hicks; Audra Jurkuvenas; Peggy Lau; Bing Ren; Amanda Millar
Journal:  Microb Pathog       Date:  2007-10-11       Impact factor: 3.738

7.  Relative roles of genetic background and variation in PspA in the ability of antibodies to PspA to protect against capsular type 3 and 4 strains of Streptococcus pneumoniae.

Authors:  Hazeline Roche; Bing Ren; Larry S McDaniel; Anders Håkansson; David E Briles
Journal:  Infect Immun       Date:  2003-08       Impact factor: 3.441

8.  Increasing penicillin and trimethoprim-sulfamethoxazole resistance in nasopharyngeal Streptococcus pneumoniae isolates from Guatemalan children, 2001--2006.

Authors:  Erica L Dueger; Edwin J Asturias; Jorge Matheu; Remei Gordillo; Olga Torres; Neal Halsey
Journal:  Int J Infect Dis       Date:  2007-11-26       Impact factor: 3.623

Review 9.  Streptococcus pneumoniae serotype 19A in Latin America and the Caribbean: a systematic review and meta-analysis, 1990-2010.

Authors:  Elizabeth Castañeda; Clara Inés Agudelo; Rodrigo De Antonio; Diego Rosselli; Claudia Calderón; Eduardo Ortega-Barria; Rómulo E Colindres
Journal:  BMC Infect Dis       Date:  2012-05-28       Impact factor: 3.090

10.  Pneumococcal surface protein A of invasive Streptococcus pneumoniae isolates from Colombian children.

Authors:  M C Vela Coral; N Fonseca; E Castañeda; J L Di Fabio; S K Hollingshead; D E Briles
Journal:  Emerg Infect Dis       Date:  2001 Sep-Oct       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.